AGTC Applied Genetic Technologies Corporation

+0.01  (+0%)
Previous Close 3.26
Open 3.27
Price To Book 0.78
Market Cap 59483286
Shares 18,165,054
Volume 11,952
Short Ratio
Av. Daily Volume 156,452

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 data due 1H 2020.
AAV Gene Therapy
CNGB3 Achromatopsia
Phase 1/2 interim data released December 12, 2018. No signs of clinical activity.
X-linked retinoschisis (XLRS)
Phase 1/2 dose escalation data due 3Q 2019. Expansion data due 4Q 2019.
AAV-based gene therapy
X-linked Retinitis Pigmentosa (XLRP)

Latest News

  1. Edited Transcript of AGTC earnings conference call or presentation 7-Feb-19 1:00pm GMT
  2. Applied Genetic Technologies: Fiscal 2Q Earnings Snapshot
  3. AGTC Announces Financial Results and Business Update for the Quarter Ended December 31, 2018
  4. Analysts Estimate Applied Genetic Technologies (AGTC) to Report a Decline in Earnings: What to Look Out for
  5. New Research: Key Drivers of Growth for Hewlett Packard Enterprise, Micron Technology, Cirrus Logic, Applied Genetic Technologies, KemPharm, and Communications — Factors of Influence, Major Initiatives and Sustained Production
  6. Applied Genetic Technologies Corporation (NASDAQ:AGTC): Time For A Financial Health Check
  7. Edited Transcript of AGTC earnings conference call or presentation 8-Nov-18 1:00pm GMT
  8. Applied Genetic Technologies Enters Oversold Territory
  9. Sell-Side Roundup: What's Next For For Applied Genetic After 50% Plunge?
  10. The Daily Biotech Pulse: Vivus Extends Supply Deal With Sandoz, Applied Genetic Snaps Ties With Biogen
  11. Today's Research Reports on Trending Tickers: Novavax and Applied Genetic Technologies
  12. AGTC Announces Topline Interim Six-Month Data from Phase 1/2 X-Linked Retinoschisis Clinical Study; Termination of Biogen Collaboration
  13. Consolidated Research: 2018 Summary Expectations for Tapestry, Mallinckrodt public limited company, Moxian, Applied Genetic Technologies, VistaGen Therapeutics, and Oasis Midstream Partners LP — Fundamental Analysis, Key Performance Indications
  14. Applied Genetic Technologies (AGTC) Tops Q1 Earnings and Revenue Estimates
  15. Earnings Preview: Applied Genetic Technologies (AGTC) Q1 Earnings Expected to Decline

SEC Filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19605442
  2. SC 13G - Statement of acquisition of beneficial ownership by individuals 19577422
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 19575237
  4. 8-K - Current report 19573430
  5. 8-K - Current report 181232226
  6. 8-K - Current report 181192960
  7. 10-Q - Quarterly report [Sections 13 or 15(d)] 181173449
  8. 8-K - Current report 181168160
  9. DEF 14A - Other definitive proxy statements 181124752
  10. 8-K - Current report 181084198